April 08, 2021
2 min read
Source / information
Published by:
Source:
Disclosure:
Datar and Willis do not report any relevant financial information. The study was funded by a research grant from RenalytixAl plc.
ADD SUBJECT TO EMAIL ALARMS
Receive an email when new articles are published
Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.
Back to Healio
A test containing plasma biomarkers was successful in predicting decline in kidney function in patients with type 2 diabetes, a spokesman reported.
Researchers evaluated the clinical utility of KidneyIntelX in primary care physicians in the treatment of diabetic kidney disease (DKD) compared to standard clinical assessment tools such as albuminuria, eGFR, age, and blood pressure.
Flat manasi
“In today’s world of increasing comorbidities associated with diabetes, patients and clinicians can be safer with their treatment plans when a simple test enables early intervention to prevent kidney disease from getting worse.” Manasi Datar, PhD, The director of Boston Healthcare Associates said in a presentation of the study results during a groundbreaking study session at the National Kidney Foundation’s virtual spring meeting.
The test uses an algorithm and electronic health data to provide a risk score in patients with early-stage DKD before clinical symptoms appear, the NKF said in a press release.
“In chronic kidney disease, and particularly in diabetic kidney disease, we have had the tools – diagnostic biomarkers and effective drugs – to prevent advanced kidney disease and kidney failure.” Kerry Willis, PhD, NKF Chief Scientific Officer said. “The challenge was to get GPs, who see the majority of patients early, to keep them busy and to identify which patients are most likely to benefit from aggressive treatment.
Kerry Willis
“KidneyIntelX has the potential to remove this critical implementation barrier so that more patients can get the right care at the right time,” said Willis.
Datar and colleagues used conjoint analysis to estimate the preferences of 401 PCPs via a web survey. Hypothetical patient profiles were then created with the following six clinical measures: albuminuria, age, blood pressure, eGFR, HbA1c and KidneyIntelX result. Each PCP considered eight profiles randomly selected from a fractional factorial design of 42 unique profiles.
For each patient, PCPs were asked whether they would prescribe an SGLT2 inhibitor (SGLT2i), increase the dose of the angiotensin II receptor blocker (ARB), or refer the patient to a nephrologist.
Of PCPs who completed the survey, investigators found that the KidneyIntelX result was “relatively more important than [standard of care] SOC tests to prescribe an SGLT2i and increase the dose of BP medication, “Datar said. “A high-risk KidneyIntelX result was associated with a significantly higher likelihood of PCPs prescribing SGLT2i with a DKD indication, increasing ARB dose and nephrologist referral compared to no test.”
Researchers from the Icahn School of Medicine and the NKF also participated in the study.
References:
Datar, M. # 380. Presented at: National Kidney Foundation Spring Clinical Meetings (virtual meeting); April 6-10, 2021.
https://link.springer.com/article/10.1007/s00125-021-05444-0.
ADD SUBJECT TO EMAIL ALARMS
Receive an email when new articles are published
Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.
Back to Healio
National Kidney Foundation Spring Clinical Meeting
